TSXV:BTI.H - Post by User
Post by
Boomskidon May 04, 2023 11:04am
105 Views
Post# 35430016
Prothena
ProthenaBest to be careful when considering any success Prothena might have with PRX012. That drug preceded the Prothena/Bioasis deal and is not an xB3 drug.
Prothena has never announced what it is or was doing with xB3. They have never made a claim that they have a drug that has any special capabilities with respect to crossing the BBB.
It also should be noted that damage to the BBB happens with Alzheimer's. It's my understanding that Alzheimer's drugs, including the amyloid-beta drugs, work mostly because a small part of a dose can pass through the leaky BBB.
In other words, efficacy of these AD drugs is dependent on how advanced the disease is and how much the BBB leaks. That makes the argument for earlier response with xB3 drugs all the more compelling.
But share prices of these AD pharmas are dependent on their work with their AD drugs. What would happen to the share price of a pharma that did a deal for xB3? Would the market interpret that as an admission that their AD isn't sufficiently capable? I think that any pharma advancing an xB3 AD drug would want to keep it secret.
And that is partially why I said ten years ago that if Bioasis didn't advance its own preclinical and clinical programs, that the company would have no story to tell because it's partners would keep their xB3 work secret.
No Bioasis collaborator, licensee or partner has ever released significant news about any of their work with xB3.
jd